Neutralization of biological activity and inhibition of receptor binding by antibodies against human thrombopoietin

Stem Cells

Volumn 16, Issue 1, 1998, Pages 54-60

  Tahara, Tomoyuki ^a   Kuwaki, Tomoaki ^a   Matsumoto, Atsushi ^a   Morita, Haruhiko ^a   Watarai, Hiroshi ^a   Inagaki, Yoshimasa ^a   Ohashi, Hideya ^a   Ogami, Kinya ^a   Miyazaki, Hiroshi ^a   Kato, Takashi ^a  

^a KIRIN BREWERY CO LTD   (Japan)

Author keywords

Active domain; c Mpl ligand; ELISA; Neutralizing antibody; Peptide antibody; Thrombopoietin

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; THROMBOPOIETIN;

ARTICLE; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; PROTEIN BINDING; PROTEIN STRUCTURE; RECEPTOR BINDING; STRUCTURE ANALYSIS;

EID: 15144347936     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.160054     Document Type: Article

References (35)

1. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-431.
2. Kaushansky K, Lok S, Holly RD et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568-571.
3. Debili N, Wendung F, Katz A et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995;86:2516-2525.
4. Nichol JL, Hokom MM, Hornkohl A et al. Megakaryocyte growth and development factor: analysis of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995;95:2973-2978.
5. Kaushansky K, Broudy VC, Lin N et al. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995;92:3234-3238.
6. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995;85:1719-1726.
7. + subpopulation of rat megakaryocyte progenitor cells exhibits high responsiveness to human thrombopoietin. Exp Hematol 1996;24:1209-1214.
8. Horie K, Miyazaki H, Hagiwara T et al. Action of thrombopoietin at the megakaryocyte progenitor level is critical for the subsequent proplatelet production. Exp Hematol 1997;25:169-176.
9. Kobayashi M, Laver JH, Kato T et al. Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors. Blood 1995;86:2494-2499.
10. Ku H, Yonemura Y, Kaushansky K et al. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 1996;87:4544-4551.
11. Matsumura I, Kanakura Y, Kato T et al. The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood 1996;88:3074-3082.
12. Sohma Y, Akahori H, Seki N et al. Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett 1994;353:57-61.
13. Kato T, Ogami K, Shimada Y et al. Purification and characterization of thrombopoietin. J Biochem 1995;118:229-236.
14. Kato T. Protein characteristics of thrombopoietin. STEM CELLS 1996;14(suppl 1):139-147.
15. de Sauvage FJ, Hass PE, Spencer SD et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533-538.
16. Harker LA, Marzec UM, Hunt P et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996;88:511-521.
17. Kenneth HP Jr, Beverly JP, Leonard GP et al. Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites. J Biol Chem 1997;272:20595-20602.
18. Tahara T. Usuki K, Sato H et al. A sensitive sandwich ELISA for measuring thrombopoietin in human serum: serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 1996;93:783-788.
19. Usuki K, Tahara T, Iki S et al. Serum thrombopoietin level in various hematological diseases. STEM CELLS 1996;14:558-565.
20. Kunishima S, Tahara T, Kato T et al. Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. Eur J Haematol 1996;57:68-71.
21. Kosugi S, Kurata Y, Tomiyama Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996;93:704-706.
22. Kimura F, Nakamura Y, Sato K et al. Cyclic change of cytokines in a patient with cyclic thrombocytopenia. Br J Haematol 1996;94:171-174.
23. Kojima S, Matsuyama T, Kodera Y et al. Measurement of endogenous plasma thrombopoietin in patients with acquired aplastic anaemia by a sensitive enzyme-linked immunosorbent assay. Br J Haematol 1997,97:538-543.
24. Ishida A, Miyakawa Y, Tanosaki R et al. Circulating endogenous thrombopoietin, interleukin-3, interleukin-6 and interleukin-11 levels in patients undergoing allogeneic bone marrow transplantation. Int J Hematol 1996;65:61-69.
25. Ichikawa N, Ishida F, Shimodaira S et al. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996;76:156-160.
26. Shimodaira S, Ishida F, Ichikawa N et al. Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thromb Haemost 1996;76:545-548.
27. Sytowski AJ, Donahue KA. Immunochemical studies of human erythropoietin using site-specific anti-peptide antibodies. J Biol Chem 1987;262:1161-1165.
28. Feldman L, Heinzerling R, Hillam RP et al. Four unique monoclonal antibodies to the putative receptor binding domain of erythropoietin inhibit the biological function of the hormone. Exp Hematol 1992;20:64-68.
29. Grodberg J, Davis KL, Sykowski AJ. Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Eur J Biochem 1993;218:597-601.
30. Wen D, Biossel J-P, Showers M et al. Erythropoietin structure-function relationships: identification of functionally important domain. J Biol Chem 1994;269:22839-22846.
31. Kato T, Oda A, Inagaki Y et al. Thrombin cleaves recombinant human thrombopoietin: one of the proteolytic events that generates truncated forms of thrombopoietin. Proc Natl Acad Sci USA 1997;94:4669-4674.
32. Monta H, Tahara T, Matsumoto A et al. Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett 1996;395:228-234.
33. Elliott S, Lorenzini T, Chang D et al. Mapping of the active site of recombinant human erythropoietin. Blood 1997;89:493-502.
34. Ramanathan L, Ingram R, Sullivan L et al. Immunochemical mapping of domains in human interleukin 4 recognized by neutralizing monoclonal antibodies. Biochemistry 1993;32:3549-3556.
35. Matsumoto A, Tahara T, Morita H et al. The native human thrombopoietin in blood: some properties of the endogenous thrombopoietin of the normal and patients with hematopoietic disorders. Blood 1996;88(suppl):544a.